Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,423 | -1,830 | -17,866 | -15,227 | -9,877 |
| Depreciation Amortization | 32 | -158 | 33 | 83 | 53 |
| Accounts receivable | 484 | 257 | 300 | -26 | 511 |
| Accounts payable and accrued liabilities | -318 | -293 | -2,751 | -609 | -3,112 |
| Other Working Capital | 166 | -36 | -2,451 | -635 | -2,601 |
| Other Operating Activity | -3 | 365 | 4,234 | 1,937 | 3,663 |
| Operating Cash Flow | $-3,062 | $-1,695 | $-18,501 | $-14,477 | $-11,363 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 3,556 | 1,351 | 17,567 | 15,842 | 10,462 |
| PPE Investments | N/A | N/A | -4 | -3 | -3 |
| Purchase Of Investment | -1,500 | N/A | N/A | -255 | N/A |
| Investing Cash Flow | $2,056 | $1,351 | $17,563 | $15,584 | $10,459 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 70 | 70 | N/A |
| Financing Cash Flow | $N/A | $N/A | $70 | $70 | $N/A |
| Beginning Cash Position | 2,130 | 2,130 | 2,998 | 2,998 | 2,998 |
| End Cash Position | 1,124 | 1,786 | 2,130 | 4,175 | 2,094 |
| Net Cash Flow | $-1,006 | $-344 | $-868 | $1,177 | $-904 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,062 | -1,695 | -18,501 | -14,477 | -11,363 |
| Capital Expenditure | N/A | N/A | -4 | -3 | -3 |
| Free Cash Flow | -3,062 | -1,695 | -18,505 | -14,480 | -11,366 |